Payment overview · 2025
General Payments
$350.95
16 reported records · 8 companies
Healthcare provider profile · identity verified
Halima Ghafoor, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEW PORT RICHEY, FL · NPI 1336354398
Verified facts
What the public records show
CMS Open Payments records show Halima Ghafoor, M.D. received $350.95 in general payments during 2025 across 16 reported records.
ABBVIE INC. accounted for 31.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ubrelvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $111.91 | 31.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $76.17 | 21.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $53.18 | 15.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.64 | 11.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.16 | 6.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.30 | 5.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.00 | 4.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.59 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $350.95 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $89.35 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $89.35 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $76.17 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $39.64 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $39.64 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.78 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.97 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 111 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
111 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
80 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 447 | 133 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 343 | 47 |
| Alprazolam | Alprazolam | 322 | 42 |
| Lisinopril | Lisinopril | 302 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 294 | 76 |
| Gabapentin | Gabapentin | 264 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 251 | 79 |
| Omeprazole | Omeprazole | 241 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 234 | 81 |
| Prednisone | Prednisone | 214 | 105 |
| Metformin Hcl | Metformin Hcl | 210 | 66 |
| Losartan Potassium | Losartan Potassium | 204 | 66 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 203 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 189 | 60 |
| Azithromycin | Azithromycin | 176 | 108 |
| Pantoprazole Sodium | Pantoprazole Sodium | 169 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 156 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 148 | 47 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 133 | 35 |
| Lorazepam | Lorazepam | 132 | 30 |
| Furosemide | Furosemide | 126 | 36 |
| Trazodone Hcl | Trazodone Hcl | 118 | 32 |
| Ozempic | Semaglutide | 111 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 28 |
| Diazepam | Diazepam | 95 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 30 |
| Clonazepam | Clonazepam | 91 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 91 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 89 | 13 |
| Ibuprofen | Ibuprofen | 88 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 20 |
| Simvastatin | Simvastatin | 84 | 28 |
| Potassium Chloride | Potassium Chloride | 82 | 25 |
| Eliquis | Apixaban | 80 | 27 |
| Atenolol | Atenolol | 79 | 16 |
| Meloxicam | Meloxicam | 79 | 28 |
| Donepezil Hcl | Donepezil Hcl | 78 | 18 |
| Tramadol Hcl | Tramadol Hcl | 76 | 15 |
| Montelukast Sodium | Montelukast Sodium | 74 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 74 | 24 |
| Fenofibrate | Fenofibrate Nanocrystallized | 70 | 23 |
| Methocarbamol | Methocarbamol | 65 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 18 |
| Pregabalin | Pregabalin | 59 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 59 | 17 |
| Alendronate Sodium | Alendronate Sodium | 52 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 18 |
| Clonidine Hcl | Clonidine Hcl | 46 | 20 |
| Allopurinol | Allopurinol | 45 | 16 |
| Finasteride | Finasteride | 44 | suppressed |
| Temazepam | Temazepam | 44 | suppressed |
| Carvedilol | Carvedilol | 43 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 15 |
| Amoxicillin | Amoxicillin | 41 | 22 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 41 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 41 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 41 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 29 |
| Spironolactone | Spironolactone | 40 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Mirtazapine | Mirtazapine | 39 | 14 |
| Cefdinir | Cefdinir | 38 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 24 |
| Baclofen | Baclofen | 37 | suppressed |
| Jardiance | Empagliflozin | 37 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 26 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Sucralfate | Sucralfate | 36 | suppressed |
| Bumetanide | Bumetanide | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Glimepiride | Glimepiride | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Lactulose | Lactulose | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 12 |
| Nitroglycerin | Nitroglycerin | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 20 |
| Lidocaine | Lidocaine | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Metronidazole | Metronidazole | 23 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | 12 |
| Famotidine | Famotidine | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 16 | 14 |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Percocet | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 12 | 11 |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $350.95 · 16 records | ABBVIE INC. | MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, XIFAXAN, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error